Paragon 28, INC 8-K filings

Paragon 28, Inc. has completed its merger with a subsidiary of Zimmer Biomet, resulting in the company becoming a wholly-owned subsidiary and the delisting of its common stock from the New York Stock Exchange.

Paragon 28, Inc. announces that its stockholders have approved the merger agreement with Zimmer, Inc., a wholly-owned subsidiary of Zimmer Biomet Holdings, Inc., at a special meeting held on April 17, 2025.

Paragon 28 updates its proxy statement with supplemental disclosures to address stockholder lawsuits and demand letters related to its pending merger with Zimmer Biomet.

Paragon 28 announces the expiration of the HSR Act waiting period, a significant step towards its acquisition by Zimmer Biomet.

Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash plus a contingent value right (CVR) that could add up to $1.00 per share, valuing the company at approximately $1.3 billion.

Zimmer Biomet has agreed to acquire Paragon 28 for $1.2 billion, including a contingent value right, to expand its presence in the high-growth foot and ankle orthopedic segment.

Paragon 28 reports preliminary unaudited revenue growth of approximately 18% for both the fourth quarter and full year 2024, signaling a strong performance in the foot and ankle orthopedic market.

Paragon 28 has appointed Dave Demski, a seasoned medical device executive, as an independent director, increasing the board size to nine members.

Paragon 28 reported strong third-quarter results, including a significant increase in revenue and improved profitability, leading to an upward revision of their full-year revenue guidance.

Paragon 28, Inc. has announced the departure of its Chief Accounting Officer, Erik Mickelson, effective September 20, 2024.

Paragon 28 announced the appointment of a new CFO, reported a 19.6% revenue increase for Q2 2024, and narrowed its full-year revenue guidance while initiating an operational efficiency strategy.

Paragon 28 has announced it will restate its financial statements for fiscal year 2023 and the first quarter of 2024 due to errors in inventory accounting.

Paragon 28, Inc. successfully held its 2024 Annual Meeting of Stockholders, electing three Class III Directors, approving executive compensation, and ratifying Deloitte & Touche LLP as its independent auditor.

Paragon 28 announced record first-quarter revenue of $61.1 million, representing 17.4% growth, and reaffirmed its full-year 2024 revenue guidance.

Paragon 28 announced the resignation of its CFO, the appointment of an interim CFO, preliminary Q1 2024 revenue, and reaffirmed its full-year 2024 revenue guidance.

Paragon 28 announced robust revenue growth for 2023 and provided a positive revenue outlook for 2024, despite a decrease in gross profit margin due to inventory write-downs.